Phase II trial DIAGNODE-2 with the diabetes vaccine Diamyd® approved to start in all participating countries
Spanish and Czech Competent Authorities and the relevant Ethics Committees have approved Diamyd Medical's application to conduct DIAGNODE-2, a pivotal follow-up placebo-controlled Phase II trial with the diabetes vaccine Diamyd® to be tested in children and young adults recently diagnosed type 1 diabetes. Previously, the trial has been approved by the Swedish Medical Products Agency and the Ethics Committee.Contract writing with all participating clinics, packing and blinding of study drugs and validation of systems and processes to be used in the trial scheduled for the autumn, is ongoing.